



European Laboratory
Research & Innovation Group

ADVANCES IN CELL BASED SCREENING IN DRUG DISCOVERY

ASTRAZENECA, MÖLNDAL

16TH - 17TH JUNE 2015

www.elrig.org



WELCOME WORDS



We are pleased to welcome you to the first ever ELRIG meeting in Scandinavia. Building on the successful launch of the Advances in Cell Based Screening conference in 2011, this year's meeting promises to deliver on a wide range of scientific topics including the latest advances in cellular screening methods applied in drug discovery.

Increasingly predictive cellular models are revolutionizing drug discovery and improving our ability to explore complex disease mechanisms and identify novel molecular therapeutics. Our diverse scientific programme has been developed to explore recent innovations in cellular screening platforms and to discuss how native cells can be paired with modern molecular biology techniques, such as Precise Genome Editing, to bring together the best from both the target-based and

phenotypic drug discovery worlds.

Today's program includes world class speakers from top academic and industrial laboratories who will showcase the exciting advances in high content imaging and phenotypic screening and how these technologies can lead to the successful identification of early hits, optimization of lead candidates and advancement of new therapeutics using more relevant cell models throughout the discovery process.

Our goal for this conference is to both inform you of the latest trends and technologies in cell based screening and to challenge you to think more broadly about how cellular assays can advance our understanding of drug targets and their role in disease biology. In addition to the scientific sessions, this 2 day event will also include an exciting poster session and an extensive vendor exhibition that will provide delegates a great opportunity to learn about and access the latest cellular assays, reagents and imaging hardware.

The planning and organization of this meeting involved the commitment and support of many individuals. In particular, I would like to thank our scientific committee members Silvio Di Castro, Ingela Parling and Alexander Kvist (all from AstraZeneca), Thomas Lundbäck (Karolinska Institutet) and Annika Sanfridson (Novo Nordisk) for their hard work and dedication in putting together an impressive scientific programme.

We would also like to thank Liz Quinn, Dermot Boylan, Tara Shanks and Rhona McDonald-Bennett of ELRIG for their support. ELRIG is a leading European not-for-profit organization that exists to provide outstanding scientific content to the life science community and a platform where academic and industry thought leaders come together to network and promote new innovations in drug discovery.

ELRIG is particularly proud to be able to provide free delegate attendance at the conference, which would not be possible without the generous support of our sponsors and exhibitors. We are grateful to them all and especially to our main sponsor this year, AstraZeneca.

We hope that today's program will be engaging, interesting and enjoyable for you.

Regards

Per-Erik Strömstedt
AstraZeneca

With Many Thanks to our main event sponsor:



SPEAKER PROGRAMME

Day 1: Tuesday 16th June

10:15 - 10:30	Opening Remarks Per-Erik Strömstedt, AstraZeneca
Materials & Models: Cellular Models & Safety Screening Session Chair: Per-Erik Strömstedt, AstraZeneca	
10:30 - 11:00	iPS Cell-Derived Models of Neurological Disorders Anna Falk, Karolinska Institutet
11:00 - 11:30	Implementing New and Novel Approaches to Impact In Vitro Drug Safety: Best Molecule by Design Andrew Brown, GlaxoSmithKline
11:30 - 12:00	hPSC as Tools in Screening Projects – Only For the Devoted(?) Anders Aspegren, Takara-Clontech Europe
12:00 - 12:30	SNAPSHOTS - Medicyte Gmb H, IntelliCyt, Sigma Aldrich, Nexcelcom, Promega
12:30 - 1:30	LUNCH - EXHIBITION - POSTERS
1:30 - 2:30	Plenary Keynote: Bridging the Gap Between Academia and Pharma at the UK National Phenotypic Screening Centre Paul Andrews, UK National Phenotypic Screening Centre, University of Dundee
Genome Editing Session Chair: Lorenz Mayr, AstraZeneca	
2:30 - 3:00	ObLiGaRe: Targeted Integration by Homology Independent Repair in Cells and Animals Marcello Maresca, AstraZeneca Mölndal
3:00 - 3:30	COFFEE BREAK
3:30 - 4:00	High Throughput Generation of Human Knockout Cell Lines Using the CRISPR/Cas9 Systems Veit Hornung, Institute for Molecular Medicine, Bonn
4:00 - 4:30	POSTER TASTERS
4:30 - 6:00	DRINKS RECEPTION - POSTER PRESENTATIONS

Day 2: Wednesday 17th June

10:15 - 10:30	Opening Remarks - Thomas Lundbäck
Platforms: High Content Imaging & Phenotypic Screening Session Chair: Per Sunnerhagen, Göteborgs Universitet	
10:30 - 11:00	Phenotypic Discovery Using Machine Learning and Image Analysis Methods Peter Horvath, Hungarian Academy of Sciences, Institute for Molecular Medicine Finland (FIMM, Helsinki)
11:00 - 11:30	A Phenotypic Screening Assay for Diamond Blackfan Anemia Candidate Drugs Johan Flygare, Lund Universitet
11:30 - 12:00	COFFEE BREAK
12:00 - 12:30	High Content Analysis for Predictive Toxicology Mikael Persson, Lundbeck A/S
12:30 - 1:00	SNAPSHOTS - Peak Analysis & Automation Ltd, Perkin Elmer, TTP Labtech, Essen Bio, JSR Micro Materials Innovation
1:00 - 2:30	LUNCH - EXHIBITION - POSTERS
Advancing Phenotypic Hits Session Chair: Thomas Lundbäck, Karolinska Institutet	
2:30 - 3:00	Target Engagement Studies Using the Cellular Thermal Shift Assay Pär Nordlund, Karolinska Institutet
3:00 - 3:30	Deconvoluting Receptors Targeted by Phenotypic Screen Hits Using the Retrogenix Cell Microarray Platform Jim Freeth, Retrogenix Ltd
3:30 - 4:00	COFFEE BREAK
4:00 - 4:30	Assessing the Importance of Intracellular Unbound Concentration Measurements for Understanding Target Engagement Per Artursson, Uppsala University
4:30 - 5:00	CLOSE OF CONFERENCE - with prize draw

ELRIG 2015 MEETINGS

Become part of the UK's most innovative life science network



DRUG DISCOVERY '15

TELFORD INTERNATIONAL CONFERENCE CENTRE

2ND - 3RD SEPTEMBER 2015

www.elrig.org

8 Tracks - 2 Days

- Innovation in Assay Development & Screening
- Metabolic & Cardiovascular Drug Discovery
- Chemistry Innovation in Lead Discovery
- Target Identification & Validation
- Phenotypic Discovery & Cell Imaging
- Oncology Drug Targets
- Cell & Gene Therapy
- New Biological Drugs & Technologies



MASS SPECTROMETRY: ADVANCES FOR DRUG DISCOVERY

INNOVATION CAMPUS, SAND HUTTON, YORK

11TH NOVEMBER 2015

www.elrig.org

Just announced!

We are delighted to announce our latest show Mass Spectrometry: Advances for Drug Discovery which will be held in York, UK.

Please see our website for all the latest announcements regarding this event.

Save the date.

For more information please contact the ELRIG team:
Email: info@elrig.org Tel: +44 (0)1904 405 177 Web: www.elrig.org

EXHIBITORS

AB Ninolab
www.ninolab.se



Horizon Discovery
www.horizondiscovery.com



Peak Analysis and Automation
www.paa-automation.com



Abcam Plc
www.abcam.com



JSR Life Sciences
www.jsrmicro.be



PerkinElmer
www.perkinelmer.com



AH diagnostics
www.ahdiagnostics.se



Kem-En-Tec Nordic
www.kem-en-tec.com



Phasefocus
www.phasefocus.com



Bigneat
www.bigneat.co.uk



Lab Automation Nordic AB
www.labautomation.nu



Promega Biotech AB
www.promega.com



BioTek Instruments
www.biotek.com



Lab Services bv
www.lab-services.nl/



Roche Diagnostics International Ltd
www.roche-diagnostics.co.uk



BlueCatBio GmbH
www.bluecatbio.com



Labcyte
www.labcyte.com



Saveen&Werner AB
<http://www.swab.se/sv/>



Cellular Dynamics International
www.cellulardynamics.com



Langton Howarth Ltd
www.langtonhowarth.co.uk



Sigma-Aldrich
www.sigmaaldrich.com



Chemometec A/S
www.chemometec.com



Liconic UK Ltd.
www.liconic.com



Tecan
www.tecan.com



Cisbio Bioassays
www.cisbio.com



Medicyte GmbH
www.medicyte.com



TTP Labtech
www.ttplabtech.com



Essen BioScience
www.essenbio.com



Nexcelom BioScience Ltd
www.nexcelom.com

